Dr. Kevin L. Mortara
Claim this profileBellin Memorial Hospital
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
10 reported clinical trials
35 drugs studied
Area of expertise
1Lung Cancer
Stage II
Stage I
Stage III
2Non-Small Cell Lung Cancer
Stage II
Stage I
Stage III
Affiliated Hospitals
Clinical Trials Kevin L. Mortara is currently running
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Blood Sample Collection
for Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.
Recruiting1 award N/A9 criteria
More about Kevin L. Mortara
Clinical Trial Related2 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Kevin L. Mortara has experience with
- Atezolizumab
- Biospecimen Collection
- Fluorouracil
- Paclitaxel
- Radiation Therapy
- Stereotactic Body Radiation Therapy
Breakdown of trials Kevin L. Mortara has run
Lung Cancer
Non-Small Cell Lung Cancer
Breast Cancer
Colorectal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kevin L. Mortara specialize in?
Kevin L. Mortara focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage II patients, or patients who are Stage I.
Is Kevin L. Mortara currently recruiting for clinical trials?
Yes, Kevin L. Mortara is currently recruiting for 5 clinical trials in Green Bay Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Kevin L. Mortara has studied deeply?
Yes, Kevin L. Mortara has studied treatments such as Atezolizumab, Biospecimen Collection, Fluorouracil.
What is the best way to schedule an appointment with Kevin L. Mortara?
Apply for one of the trials that Kevin L. Mortara is conducting.
What is the office address of Kevin L. Mortara?
The office of Kevin L. Mortara is located at: Bellin Memorial Hospital, Green Bay, Wisconsin 54301 United States. This is the address for their practice at the Bellin Memorial Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.